Delirium - Global Strategic Business Report

The global market for Delirium was estimated at US$32.7 Million in 2024 and is projected to reach US$41.5 Million by 2030, growing at a CAGR of 4.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Delirium market.

Global Delirium Treatment Market - Key Trends & Drivers Summarized

Why Is Delirium Emerging as a Priority Concern in Acute and Elderly Care?

Delirium, characterized by a sudden onset of confusion, disorientation, and fluctuating levels of consciousness, is increasingly recognized as a serious complication in hospitalized patients especially among the elderly, ICU patients, and post-operative individuals. Its impact is often underestimated, yet delirium is associated with increased morbidity, prolonged hospital stays, higher healthcare costs, and a greater risk of long-term cognitive decline. As global populations age and the burden of chronic illnesses requiring hospitalization rises, the incidence of delirium is surging across healthcare systems.

Healthcare providers are placing growing emphasis on early identification and prevention of delirium, especially in geriatric wards, surgical recovery units, and intensive care settings. The condition is commonly triggered by multiple risk factors such as infections, polypharmacy, metabolic imbalances, and sudden environmental changes in vulnerable patients. Delirium is no longer viewed as an inevitable part of hospitalization but as a preventable and treatable syndrome, prompting the development of multidisciplinary protocols that combine pharmacological, non-pharmacological, and environmental strategies to manage it effectively.

How Are Diagnostic and Monitoring Tools Evolving to Detect Delirium More Effectively?

Early and accurate detection of delirium remains a critical challenge due to its fluctuating nature and symptom overlap with dementia and depression. This has led to the development and widespread adoption of standardized screening tools such as the Confusion Assessment Method (CAM), the Intensive Care Delirium Screening Checklist (ICDSC), and the 4AT screening tool. These instruments are now integral to clinical protocols, especially in emergency departments, surgical recovery, and geriatric care units. Continuous patient monitoring technologies are also being integrated into ICU settings to track cognitive fluctuations and physiological stress indicators that may signal the onset of delirium.

Digital health innovations are also entering the diagnostic space. AI-powered clinical decision support systems and electronic health record (EHR)-linked alert systems are being deployed to identify high-risk patients based on real-time clinical data. These platforms enable timely interventions such as medication review, environmental modification, hydration support, and sensory reorientation. Mobile apps and bedside assessment tools designed for non-specialist caregivers are also gaining attention, helping improve detection rates in home care and long-term care facilities.

What Therapeutic Strategies Are Gaining Ground in the Management of Delirium?

Management of delirium emphasizes prevention, early intervention, and minimizing underlying triggers. Non-pharmacological interventions remain the gold standard for both prevention and treatment, especially in elderly and post-operative patients. These include orientation strategies, sleep hygiene protocols, noise reduction, pain management, and vision/hearing aids to reduce sensory deprivation. Multicomponent care models such as the Hospital Elder Life Program (HELP) are being adopted by hospitals to systematically address delirium risk factors and improve patient outcomes.

Pharmacological treatments are typically reserved for cases of severe agitation or risk to self and others. Antipsychotics such as haloperidol and atypical agents like quetiapine and olanzapine are sometimes used, although evidence supporting their routine use remains mixed. Research into alternative pharmacotherapies is ongoing, including melatonin and dexmedetomidine for sleep-wake cycle stabilization and neuroprotective agents to minimize cognitive injury. Personalized medicine approaches that account for underlying cognitive status, co-morbidities, and drug sensitivity are becoming increasingly important in delirium care pathways.

What Are the Main Forces Driving the Expansion of the Delirium Management Market?

The growth in the delirium management market is driven by several factors, including the rising global geriatric population, increased hospitalization rates among patients with chronic conditions, and growing awareness among healthcare professionals about the risks and consequences of delirium. As hospitals seek to reduce readmission rates, ICU complications, and long-term cognitive impairment, delirium prevention protocols are being prioritized as part of overall quality care initiatives. National health agencies and accreditation bodies are mandating delirium assessment as part of safety and performance standards.

Technological integration is another growth catalyst, with EHR-based screening tools, AI-enabled clinical decision support, and wearable cognitive monitoring devices streamlining the detection and management process. In parallel, the expansion of multidisciplinary care teams involving geriatricians, neurologists, nurses, and pharmacists is enhancing the standardization of treatment approaches. The push for home-based recovery and remote monitoring post-surgery or ICU stay is also increasing the relevance of community-level delirium care solutions. As healthcare systems become more proactive in addressing neurocognitive complications, the delirium treatment and monitoring landscape is set for significant clinical and commercial expansion

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Hyperactive Type segment, which is expected to reach US$24.6 Million by 2030 with a CAGR of a 5.0%. The Hypoactive Type segment is also set to grow at 2.6% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $8.9 Million in 2024, and China, forecasted to grow at an impressive 7.6% CAGR to reach $8.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Delirium Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Delirium Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Delirium Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AbbVie Inc., Acadia Pharmaceuticals Inc., Akorn Incorporated, Alkermes plc, and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 44 companies featured in this Delirium market report include:

• AbbVie Inc.
• Acadia Pharmaceuticals Inc.
• Akorn Incorporated
• Alkermes plc
• Apotex Inc.
• BioXcel Therapeutics, Inc.
• Ceribell, Inc.
• Delix Therapeutics
• Eleusis Ltd.
• Fresenius Kabi AG
• Glenmark Pharmaceuticals Ltd.
• Johnson & Johnson
• Mind Medicine (MindMed) Inc.
• Mylan N.V.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.